Tech Company Financing Transactions
Enlibrium Funding Round
On 12/4/2015, Enlibrium raised $15 million in Series A investment from Avalon Ventures, TPG Biotech and Correlation Ventures.
Transaction Overview
Company Name
Announced On
12/4/2015
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
Avalon Ventures (Lead Investor) (Jay Lichter)
TPG Biotech (Lead Investor) (Heather Preston)
Proceeds Purpose
The financing is expected to provide sufficient capital to advance Enlibrium's lead compounds through Phase 1 clinical trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Enlibrium is developing novel drugs based on metformin to treat a range of different cancers by reducing cancer energy consumption and reestablishing energy balance. Given their high growth rate and energy requirements, cancers are particularly sensitive to agents that reduce their energy production.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Campbell
Browse more venture capital transactions:
Prev: 12/4/2015: Trufa venture capital transaction
Next: 12/4/2015: Soundtrap venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs